Royalty Pharma, a U.S. investment group that specializes in drug companies, criticized Elan's recent $1 billion purchase for "21 percent of selected royalties owned by Theravance when all of Theravance was trading at $3.5 billion." Royalty Pharma said its latest offer for Elan was contingent on shareholders voting against the Theravance deal and tw
AB SCIEX, a global leader in analytical technologies, today announced the launch of the 3200 MD CE-IVDD series for general in vitro diagnostic use in Europe. We are focused on meeting the medical, technological and compliance needs of clinical diagnostic laboratories and hospitals,? said Rainer Blair, President of AB SCIEX. The use of LC/MS
By a News Reporter-Staff News Editor at Clinical Trials Week AbbVie announced that its investigational direct-acting antiviral combination with and without ribavirin for the treatment of genotype 1 hepatitis C virus infection has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration. The designation is based, in part,
Accelera Innovations, Inc., a Delaware corporation, is a healthcare service company which will initially focus on its technology assets that were licensed to the Company by our majority shareholder Synergistic Holdings, LLC, a privately-held company organized under the laws of Illinois to further develop, pursuant to which the Company was granted a
PARSIPPANY, N.J. and DUBLIN, May 20, 2013/ PRNewswire/ Actavis, Inc. and Warner Chilcott plc today announced they have entered into a definitive agreement under which Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. The proposed transaction has been unanimously approved by the Boards
By a News Reporter-Staff News Editor at Managed Care Weekly Digest eClinicalWorks , a leader in ambulatory healthcare IT solutions, announces that Amarillo Legacy Medical ACO, the first Accountable Care Organization in the Texas Panhandle, has selected eClinicalWorks Care Coordination Medical Record? for advancing its ACO objectives, coordina
DUBLIN, Ireland, 2013-05-20 15:00 CEST In accordance with Rule 2.10 of the Irish Takeover Rules, Warner Chilcott plc confirms that, as of the close of business on May 15, 2013, the Company's issued share capital consisted of 250,922,431 ordinary shares, par value US $0.01 per share. The Company Warner Chilcott is a leading specialty pharmaceutica
Actavis buying Warner Chilcott in $8.5 B deal. NEW YORK - Actavis is buying Warner Chilcott in an all-stock transaction valued at about $8.5 billion which would create the third-biggest specialty pharmaceutical company in the U.S. It also follows reports that Parsippany, N.J.- based Actavis rebuffed takeover bids from companies including Mylan Inc.
By a News Reporter-Staff News Editor at Clinical Trials Week BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2013. "We are pleased that our recent interactions with the FDA have defined a pathway to file a peramivir NDA for regulatory approval in the U.S.," said Jon P. Stonehouse, President& Chief
Dublin- Research and Markets has announced the addition of the updated "BioPharmaceutical Industry in China- An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities& Challenges" report to their offering. BioPharmaceutical Industry in China- An In Dept
Dublin- Research and Markets has announced the addition of the "Booming Medical Tourism in Malaysia" report to their offering. Healthcare expense in developed countries together with the issue of time is making people seek affordable healthcare services in developing countries such as Malaysia. In their latest research study, Booming Medical Touris
Today, Committee on Ways and Means Health Subcommittee Chairman Kevin Brady, along with Reps. Pat Tiberi, Peter Roskam, Vern Buchanan, Aaron Schock, Tom Reed, Mike Kelly, Jim Renacci and Morgan Griffith introduced the Medicare Hospital Wage Index Equity Act of 2013.. As former Centers for Medicare and Medicaid Services administrator under President
Pat Tiberi, Peter Roskam, Vern Buchanan, Aaron Schock, Tom Reed, Mike Kelly, Jim Renacci and Morgan Griffith introduced the Medicare Hospital Wage Index Equity Act of 2013.. As former Centers for Medicare and Medicaid Services administrator under President Obama, Donald Berwick, said, "What Massachusetts gets comes from everybody else." Because of
May 20 Danville Regional Medical Center Home Health Services recently announced that it is now using the Patient Information Logistics Solution System for in-home monitoring and disease management support of certain patients. The system is the newest advancement in remote patient condition monitoring, collecting patient readings such as weight, b
This document contains "forward-looking statements". All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of manag
This prospective study conducted at Vanderbilt University Medical Center evaluated the clinical utility of Corus CAD, a blood-based gene expression test for the assessment of obstructive coronary artery disease, in decision-making by cardiologists regarding their diagnostic testing strategy. Better methods are needed to more accurately assess...
Dublin- Research and Markets has announced the addition of the "Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market" report to their offering. The Healthcare and Education Reconciliation Act changed the device tax to a flat sales or excise tax of 2.3% on all devices regulated by the Food and Drug Administration, whic
By a News Reporter-Staff News Editor at Managed Care Weekly Digest Chicago Health System ACO, part of the Vanguard Health Systems, has selected Care Team Connect to power care management for their ACO population of about 10,000 patients. The announcement comes on the heels of positive outcomes achieved at the Michigan Pioneer ACO which is also pa
Published ahead of print in Circulation, May 7 th this research is the result of a collaboration between Erasmus Medical Center, Rotterdam, the Netherlands and the pathology team of Dr. Renu Virmani of the Cardiovascular Pathology Institute, Gaithersburg, Maryland. This is the first time any research has reported the frequency and composition of de
Such risks and uncertainties include, but are not limited to, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new bu
Covidien, a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced that its Nellcor? pulse oximetry portfolio, which is used to measure arterial oxygen saturation, has received U.S. Food and Drug Administration 510 clearance for motion claims. This makes Covidien
FDA, in a manner similar to its prescription drug regulation, regulates diagnostic test kits and at-home patient testing products similarly to the regulation of prescription medicine. Our subsidiaries, Pharma Tech Solutions, Inc. and PDA Services, Inc. operate in several healthcare products distribution channels. FDA cleared the Shasta Genstrip pro
Presented today at the 18 th Annual International Society for Pharmacoeconomics and Outcomes Research conference in New Orleans, the study analyzed nearly 650 Phase 3 and Phase 2/ 3 diabetes clinical trials from the clinicaltrials.gov database. However, in the area of diabetes, one of the most prevalent diseases in the United States, patient-report
In August 2008, the FDA accepted the NDA for Remoxy that had been submitted by King and PT. In December 2008, the FDA issued a "complete response" letter. In June 2011, we and PT announced that a "complete response" letter was received from the FDA with regard to the resubmission of the NDA.
Series A investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital. eFFECTOR co-founders also include Davide Ruggero, Ph.D., holder of the Helen Diller Family Endowed Chair in Basic Research at UCSF and a pioneer in the field of translation con
